<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955251</url>
  </required_header>
  <id_info>
    <org_study_id>M15-819</org_study_id>
    <secondary_id>2016-001461-88</secondary_id>
    <nct_id>NCT02955251</nct_id>
  </id_info>
  <brief_title>A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2
      dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK)
      profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in
      participants with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2016</start_date>
  <completion_date type="Actual">October 29, 2019</completion_date>
  <primary_completion_date type="Actual">October 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>First dose of study drug through at least 100 days after end of treatment; up to 2 years after last participants first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RPTD) of ABBV-428 when administered as monotherapy or in combination with nivolumab</measure>
    <time_frame>1 day of study drug administration within the 28-day cycle at the designated cohort dose</time_frame>
    <description>If a maximum tolerated dose (MTD) is reached, the RPTD of ABBV-428 will not be a dose higher than the defined MTD, and will be selected based on the type(s) and occurrence(s) of dose limiting toxicities which occur in addition to the MTD. If a MTD is not reached, then the RPTD will be defined based on the safety and pharmacokinetic data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) of ABBV-428</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2) of ABBV-428</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of ABBV-428</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of ABBV-428 when administered as monotherapy or in combination with nivolumab</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The highest dose level at which less than 2 of 6 participants or less than 33% of (if cohort is expanded beyond 6) participants experience a dose limiting toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of ABBV-428</measure>
    <time_frame>Up to 30 days after a 24-month treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response (DOR)</measure>
    <time_frame>Up to 30 days after a 24-month of treatment period</time_frame>
    <description>DOR defined as the time from the initial objective response to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Up to 30 days after a 24-month of treatment period</time_frame>
    <description>CBR defined as the proportion of subjects with a confirmed partial response (PR), complete response (CR), or stable disease for at least 24 weeks to the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 30 days after a 24-month of treatment period</time_frame>
    <description>PFS time is defined as the time from the first dose of ABBV-428 to disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 30 days after a 24-month of treatment period</time_frame>
    <description>ORR is defined as the proportion of subjects with a confirmed partial or complete response to the treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Advanced Solid Tumors Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-428 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, B, and C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional participants (with ovarian cancer, NSCLC, etc.) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-428.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-428 plus nivolumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-428 plus nivolumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-428</intervention_name>
    <description>ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm A, B, and C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have an advanced solid tumor that has progressed on standard
             therapies known to provide clinical benefit or the participants are intolerant to such
             therapies.

          -  Participants have adequate bone marrow, renal, hepatic and coagulation function.

          -  For all dose expansion arms, participants must have measurable disease per Response
             Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

          -  Participants in combination therapy cohorts must have an advanced solid tumor where
             the use of nivolumab is standard therapy.

        Exclusion Criteria:

          -  Active or prior documented autoimmune disease in the last 2 years. Participants with
             childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or
             psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.

          -  Current or prior use of immunosuppressive medication within 14 days prior to the first
             dose (with certain exceptions).

          -  History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic
             leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis.

          -  Confirmed positive test results for human immunodeficiency virus (HIV), or
             participants with chronic or active hepatitis B or C. Participants who have a history
             of hepatitis B or C who have undetectable HBV DNA or HCV RNA after anti-viral therapy
             may be enrolled.

          -  Prior grade greater than or equal to 3 immune-mediated neurotoxicity or pneumonitis
             (or any other unresolved or symptomatic adverse event in the last 3 months) while
             receiving immunotherapy.

          -  Male participants who are considering fathering a child or donating sperm during the
             study or for at least 3 or 5 months (for monotherapy and combination therapy
             participants, respectively) after the last dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth Research Institute - Pima /ID# 155461</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258-2345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center - Main /ID# 154439</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 154440</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center /ID# 170665</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System /ID# 154437</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Texas Medical Center /ID# 154441</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics /ID# 154442</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse /ID# 163131</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Cancer Institute /ID# 163132</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie /ID# 202391</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie /ID# 162258</name>
      <address>
        <city>Paris CEDEX 05</city>
        <state>Ile-de-France</state>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy /ID# 162257</name>
      <address>
        <city>Villejuif</city>
        <state>Ile-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone /ID# 162256</name>
      <address>
        <city>Marseille CEDEX 05</city>
        <state>Provence-Alpes-Cote-d Azur</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard /ID# 168072</name>
      <address>
        <city>Lyon CEDEX 08</city>
        <state>Rhone</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Univ Hosp /ID# 169034</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>Advanced solid tumor</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>Non-squamous NSCLC</keyword>
  <keyword>Ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

